Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dexcom ( (DXCM) ) just unveiled an update.
On February 26, 2026, Dexcom’s board expanded to twelve members and appointed Rick Osterloh, Google’s Senior Vice President for Platforms & Devices, as an independent director with a term running until the 2026 annual shareholder meeting. He joins the Compensation and Technology committees, receives standard director indemnification, and was granted restricted stock units under Dexcom’s non-employee director compensation program, aligning his incentives with long-term shareholder interests.
Osterloh’s appointment brings deep expertise in consumer hardware, platforms, and large-scale product operations from his leadership roles at Google, Motorola, and other major technology firms. Dexcom’s leadership highlighted that his experience integrating advanced hardware, software, and AI should support the company’s long‑term product strategy in biosensing and metabolic health, potentially strengthening its innovation pipeline and competitive position in digital health and wearables.
The most recent analyst rating on (DXCM) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.
Spark’s Take on DXCM Stock
According to Spark, TipRanks’ AI Analyst, DXCM is a Outperform.
DXCM scores well on fundamentals and forward guidance, driven by strong revenue/FCF growth, improving leverage, and expected 2026 margin expansion. The overall score is held back by weak technicals (below key moving averages with negative MACD) and a relatively high P/E with no dividend yield support.
To see Spark’s full report on DXCM stock, click here.
More about Dexcom
Dexcom, Inc., based in San Diego, is a global leader in glucose biosensing technology that helps people manage diabetes and track their glucose levels. Founded in 1999, the company has pioneered continuous glucose monitoring for more than 25 years, focusing on innovative biosensing solutions that empower users to improve metabolic health and live more confidently.
Average Trading Volume: 5,242,089
Technical Sentiment Signal: Sell
Current Market Cap: $28.13B
Learn more about DXCM stock on TipRanks’ Stock Analysis page.